Clinical Trials Logo

Filter by:
NCT ID: NCT04044651 Withdrawn - Clinical trials for Hepatocellular Carcinoma

Lenvatinib Plus Nivolumab Versus Lenvatinib for Advanced Hepatocellular Carcinoma With Hepatitis B Virus Infection

Start date: October 30, 2019
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to investigate the efficacy and safety of lenvatinib plus nivolumab compared with lenvatinib monotherapy for patients with advanced hepatitis B virus infection-related hepatocellular carcinoma.

NCT ID: NCT04044378 Withdrawn - Pediatric Cancer Clinical Trials

Famitinib Plus Camrelizumab & Famitinib Alone & Famitinib Plus Ifosfamide in Advanced Osteosarcoma

Start date: August 15, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

Results of previous study showed high objective response but short-term activity of anti-angiogenesis tyrosine kinase inhibitors in advanced osteosarcoma. Given the recent success of immunotherapies, combinations of antiangiogenics with immune checkpoint blockers have become an attractive strategy. The investigators had completed an prospective phase 2 trial of the combination of apatinib and camrelizumab on advanced osteosarcoma and showed prolonged progression-free survival for this combination. Famitinib is a novel tyrosine kinase inhibitor targeting VEGFR-2, -3 and FGFR-1, -2, -3, -4 with high affinity, which showed broad antitumor activity against a variety of xenograft models. A Study to Compare the Efficacy and Safety of Levatinib with or without Ifosfamide and Etoposide in Children, Adolescents and Young Adults With Relapsed and Refractory Osteosarcoma showed promising median PFS of 11.3 months. Thus we also try to investigate the combination efficacy of TKIs with chemotherapy in advanced osteosarcoma. This study aims to investigate the recommended phase 2 dose for pediatric use of famitinib in combination with camrelizumab and trys to explore the efficacy and safety for single drug famitinib, famitinib and camrelizumab and famitinib and ifosfamide in patients with inoperable high-grade osteosarcoma progressing after chemotherapy.

NCT ID: NCT04034615 Withdrawn - Cicatrix Clinical Trials

The Long-term Effect of Perinatal Tissue Mesenchyme Stem Cells in the Treatment for Caesarean Section Scars

Start date: May 20, 2021
Phase: Phase 2
Study type: Interventional

The study is to investigate the long-term efficacy of perinatal tissue mesenchyme stem cells treatment on the appearance of a caesarean scar as compared to a similar untreated scar.

NCT ID: NCT04019470 Withdrawn - Clinical trials for Brain Tumor, Pediatric

Immunomodulation Analysis of Radiation Therapy in Pediatric Malignant Brain Tumors

Start date: February 1, 2019
Phase:
Study type: Observational

To investigate the effect of radiotherapy on peripheral blood immune cell composition and function in pediatric malignant brain tumor patients.

NCT ID: NCT03997292 Withdrawn - Ischemic Stroke Clinical Trials

Intravenous Thrombolysis Registry for Acute Ischemic Stroke in China

Start date: March 1, 2018
Phase:
Study type: Observational

To analyze the real situation of intravenous thrombolysis in acute ischemic stroke in China

NCT ID: NCT03991104 Withdrawn - Esophageal Cancer Clinical Trials

SOX-based CRT for Esophageal Cancer.

Start date: May 1, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

Patients with esophageal cancer that had locally advanced diseases or with unresectable diseases are being asked to participate in this phase I/II study. This phase I/II study is being conducted to determine the maximum-tolerated dose (MTD), dose-limiting toxicity (DLT), and efficacy of IMRT combined with S-1 and Oxaliplatin (SOX) based chemotherapy for unresectable locally advanced esophageal cancer.

NCT ID: NCT03985462 Withdrawn - Clinical trials for Stem Cell Transplant Complications

Very Small Embryonic-like Stem Cells for Ovary

Start date: July 3, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

The aim of this study is the safety and efficacy of autologous very small embryonic-like stem cells(VSELs) to premature ovarian failure.

NCT ID: NCT03976206 Withdrawn - Clinical trials for Stem Cell Transplant Complications

Very Small Embryonic-like Stem Cells for Facial Skin Antiaging

Start date: July 6, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

The aim of this study is the safety and efficacy of autologous very small embryonic-like stem cells(VSELs) to facial skin antiaging.

NCT ID: NCT03975101 Withdrawn - Knee Osteoarthritis Clinical Trials

Very Small Embryonic-like Stem Cells for Knee Osteoarthritis

Start date: July 5, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

The aim of this study is the safety and efficacy of autologous very small embryonic-like stem cells(VSELs) to knee osteoarthritis.

NCT ID: NCT03973021 Withdrawn - Clinical trials for Organic Erectile Dysfunction

Very Small Embryonic-like Stem Cells for Erectile Dysfunction

Start date: July 1, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

The aim of this study is the safety and efficacy of autologous very small embryonic-like stem cells(VSELs) to organic erectile dysfunction, such as those associated with metabolic syndrome or the treatment of prostate cancer.